Antihistamines in Rhinitis and Asthma
Just several years after the concept “allergy” was coined about a century ago , histamine was identified by Sir Henry Dale  and subsequently emerged as one of the most important allergy substrates. This marked the onset of a spiral of scientific achievements, which resulted in the development of multiple drug formulations used in the prevention and treatment of allergic disorders and in elucidation of the pleiotropic role histamine plays in health and disease.
Histamine belongs to a group of locally produced tissue hormones (including serotonin and others) referred to as “autacoids.” 1 It plays a vital role in the regulation of the many important functions related to circadian influences, adaptation to environment and stress. Conversely, histamine is intimately implicated in the patho-genesis of allergic diseases, which develop as defective systemic trait of genetically predisposed individuals and may have different organ expressions. Airway allergic morbidity in particular accounts for a lot of individual suffering and disability, and poses a substantial economic burden to society [3, 4]. Therefore, the correct prescription of existing antihistamine products and the development of new and more effective formulations devoid of unwanted effects are two important avenues in the global crusade to control these morbidities affecting millions of people.
KeywordsAllergic Rhinitis Allergy Clin Immunol Nasal Congestion Seasonal Allergic Rhinitis Allergy Asthma Immunol
Unable to display preview. Download preview PDF.
- 1.von Pirquet C (1906) Allergie. Munchen Med Wehnschr 53: 1457Google Scholar
- 4.Global initiative for asthma. Global strategy for asthma management and prevention. NHLBI/ WHO workshop report. Revision 2006. NIH publication no. 02-3659Google Scholar
- 9.Jauregui I, Mullol J, Bartra J, del Cuvillo A, Davila I, Montoro J, Sastre J, Valero AL (2006) H1 antihistamines: psychomotor performance and driving. J Investig Allergol Clin Immunol 16: S37–S44Google Scholar
- 11.Ash A, Schild H (1966) Receptors mediating some actions of histamine. Br J Pharmacol 27: 427–439Google Scholar
- 14.Nguyen T, Shapiro DA, George SR, Setola V, Lee DK, Cheng R, Rauser L, Lee SP, Lynch KR, Roth BL, O'Dowd BF (2001) Discovery of a novel member of the histamine receptor family. J Mol Pharmacol 59: 427–433Google Scholar
- 16.Bovet D, Staub A-M (1937) Protective action of phenol ethers in the course of histamine intoxication. C R Soc Biol (Paris) 124: 547–549 (French)Google Scholar
- 17.Passalaqua G, Canonica GW, Bousquet J (2002) Structure and classification of H1-antihistamines and overview of their activities. In: Simons FER (ed) Histamine and H1-antihistamines in allergic disease. Marcel Dekker Inc, New York, pp 65–100Google Scholar
- 24.International Rhinitis Management Working Group (1994) International consensus report on diagnosis and management of rhinitis. Allergy 49(19 Suppl): 1–34Google Scholar
- 31.van Wijk RG, de Graaf-in ‘t Veld C, Garrelds IM (1999) Nasal hyperreactivity. Rhinology 37: 50–55Google Scholar
- 32.Bousquet J, Van Cauwenberge P, Bachert C, Canonica GW, Demoly P, Durham SR, Fokkens W, Lockey R, Meltzer EO, Mullol J, Naclerio RM, Price D, Simons FER, Vignola AM, Warner JO (2003) Requirements for medications commonly used in the treatment of allergic rhinitis. Allergy 58: 192–197CrossRefPubMedGoogle Scholar
- 33.Simons FE, McMillan JL, Simons KJ (1990) A double-blind, single-dose, crossover comparison of cetirizine, terfenadine, loratadine, astemizole, and chlorpheniramine versus placebo: suppressive effects on histamine-induced wheals and flares during 24 h in normal subjects. J Allergy Clin Immunol 86: 540–547.CrossRefPubMedGoogle Scholar
- 34.Grant JA, Danielson L, Rihoux JP, DeVos C (1999) A double-blind, single-dose, crossover comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadine, and loratadine versus placebo: suppression of histamine induced wheal and flare response for 24 h in healthy male subjects. Allergy 54: 700–707CrossRefPubMedGoogle Scholar
- 47.Cruz AA, Popov TA, Pawankar R, Annesi-Maesano I, Fokkens W, Kemp J, Ohta K, Price D, Bousquet J (2007) Common characteristics of upper and lower airways disease in rhinitis and asthma: ARIA update, in collaboration with GA 2 LEN. Allergy (in press)Google Scholar
- 54.Baena-Cagnani CE, Berger WE, DuBuske LM, Gurne SE, Stryszak P, Lorber R, Danzig M (2003) Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2-agonists in patients with seasonal allergic rhinitis and asthma. Int Arch Allergy Immunol 130: 307–313CrossRefPubMedGoogle Scholar